STRATA Skin Sciences Completes $2.1 Million Direct Offering With Participation from Insiders
STRATA Skin Sciences (NASDAQ: SSKN) has successfully closed a $2.1 million registered direct offering of common stock. The company issued 665,136 shares at an average price of $3.16 per share. This offering was conducted under a previously filed and effective shelf registration statement. Notably, insiders and existing shareholders participated in the offering, which the company views as a sign of confidence in its strategic plan and execution abilities.
Dr. Dolev Rafaeli, STRATA's President and CEO, emphasized that this financing will extend the company's cash runway and demonstrates conviction in their path to profitability. STRATA Skin Sciences is a medical technology company focused on developing and marketing innovative products for dermatologic conditions.
STRATA Skin Sciences (NASDAQ: SSKN) ha concluso con successo un offerta diretta registrata di $2,1 milioni di azioni ordinarie. L'azienda ha emesso 665.136 azioni a un prezzo medio di $3,16 per azione. Questa offerta è stata effettuata sotto una dichiarazione di registrazione già depositata e efficace. È interessante notare che i membri interni e gli azionisti esistenti hanno partecipato all'offerta, il che l'azienda vede come un segnale di fiducia nel suo piano strategico e nelle sue capacità di esecuzione.
Il Dr. Dolev Rafaeli, Presidente e CEO di STRATA, ha sottolineato che questo finanziamento estenderà la liquidità dell'azienda e dimostra la determinazione nel loro cammino verso la redditività. STRATA Skin Sciences è una società di tecnologia medica focalizzata nello sviluppo e commercializzazione di prodotti innovativi per le condizioni dermatologiche.
STRATA Skin Sciences (NASDAQ: SSKN) ha cerrado con éxito una oferta directa registrada de $2.1 millones de acciones ordinarias. La compañía emitió 665,136 acciones a un precio promedio de $3.16 por acción. Esta oferta se llevó a cabo bajo una declaración de registro previamente presentada y efectiva. Es notable que los miembros internos y los accionistas existentes participaron en la oferta, lo que la empresa considera como una señal de confianza en su plan estratégico y capacidades de ejecución.
El Dr. Dolev Rafaeli, Presidente y CEO de STRATA, enfatizó que este financiamiento ampliará el capital disponible de la empresa y demuestra la convicción en su camino hacia la rentabilidad. STRATA Skin Sciences es una empresa de tecnología médica enfocada en desarrollar y comercializar productos innovadores para condiciones dermatológicas.
STRATA Skin Sciences (NASDAQ: SSKN)는 210만 달러 규모의 등록된 직접 공모를 성공적으로 마무리했습니다. 회사는 665,136주를 평균 주당 3.16달러의 가격으로 발행했습니다. 이 공모는 이전에 제출된 유효한 선등록 명세서에 따라 진행되었습니다. 특히, 인사들과 기존 주주들이 공모에 참여했습니다, 이는 회사의 전략적 계획과 실행 능력에 대한 신뢰의 표시로 여겨집니다.
STRATA의 사장 겸 CEO인 Dr. Dolev Rafaeli는 이번 자금 조달이 회사의 자금 조달 기간을 연장할 것이라는 점과 그들의 수익성 달성 경로에 대한 확신을 보여준다고 강조했습니다. STRATA Skin Sciences는 피부과 질환을 위한 혁신적인 제품을 개발하고 마케팅하는 데 집중하는 의학 기술 회사입니다.
STRATA Skin Sciences (NASDAQ: SSKN) a réussi à clôturer une offre directe enregistrée de 2,1 millions de dollars d'actions ordinaires. L'entreprise a émis 665.136 actions à un prix moyen de 3,16 dollars par action. Cette offre a été réalisée sous une déclaration d'enregistrement déjà déposée et effective. Notamment, les initiés et les actionnaires existants ont participé à l'offre, ce que l'entreprise considère comme un signe de confiance dans son plan stratégique et ses capacités d'exécution.
Dr. Dolev Rafaeli, Président et CEO de STRATA, a souligné que ce financement prolongera la trésorerie de l'entreprise et démontre leur conviction dans leur chemin vers la rentabilité. STRATA Skin Sciences est une entreprise de technologie médicale axée sur le développement et la commercialisation de produits innovants pour les conditions dermatologiques.
STRATA Skin Sciences (NASDAQ: SSKN) hat erfolgreich eine registrierte Direktemission über 2,1 Millionen Dollar von Stammaktien abgeschlossen. Das Unternehmen hat 665.136 Aktien zu einem Durchschnittspreis von 3,16 Dollar pro Aktie ausgegeben. Diese Emission wurde unter einer zuvor eingereichten und wirksamen Shelf-Registrierungsmitteilung durchgeführt. Bemerkenswert ist, dass Insider und bestehende Aktionäre teilgenommen haben, was das Unternehmen als Zeichen des Vertrauens in seinen strategischen Plan und seine Umsetzungskompetenzen ansieht.
Dr. Dolev Rafaeli, Präsident und CEO von STRATA, betonte, dass diese Finanzierung den finanziellen Spielraum des Unternehmens erweitern wird und Überzeugung in ihrem Weg zur Rentabilität demonstriert. STRATA Skin Sciences ist ein Medizintechnologieunternehmen, das sich auf die Entwicklung und Vermarktung innovativer Produkte für dermatologische Erkrankungen konzentriert.
- Raised $2.1 million in gross proceeds through direct offering
- Insider and existing shareholder participation indicates confidence in company strategy
- Financing expected to extend cash runway
- Offering priced at-the-market under Nasdaq rules
- Potential dilution of existing shareholders due to issuance of new shares
Insider Participation: The involvement of insiders and existing shareholders in the direct offering is a positive signal to the market. It indicates confidence in the company’s strategic direction and financial health. Insider purchases are often considered a sign that those closest to the company's operations believe in its future prospects and consider the stock undervalued.
Financial Impact: The $2.10 million raised will bolster STRATA’s cash reserves, providing the company with more financial flexibility. This is important for a medical technology company that may require substantial capital for research, development and commercialization of its products. The timing of the offering, priced at-the-market, suggests the company is leveraging current market conditions effectively.
Dilution Considerations: While the issuance of 665,136 new shares will dilute existing shareholders’ equity, the impact may be offset by the expected benefits from increased cash reserves and potential strategic investments. Shareholders may view the dilution as a necessary step for long-term growth, particularly given the participation of insiders.
Market Perception: The completion of the $2.1 million direct offering under Nasdaq rules signals to the market that STRATA has the regulatory compliance and market presence to attract investment. The use of a “shelf” registration statement allows the company to raise capital as needed without undergoing a lengthy registration process each time, thereby enhancing responsiveness to market opportunities.
Strategic Implications: The funds raised can aid in accelerating the development and commercialization of new dermatologic treatments. This aligns with STRATA’s core mission and can reinforce its competitive position in the medical technology sector. Additionally, by extending its cash runway, the company can invest in strategic initiatives without immediate pressure to achieve short-term profitability.
Investor Confidence: The successful funding round, especially with insider participation, may enhance investor confidence. It suggests that those with the most insight into the company's operations are willing to invest further, potentially attracting new investors who were previously on the fence.
Innovation and Development: The infusion of $2.1 million enables STRATA to continue its R&D efforts. In the medical technology space, continuous innovation is key to maintaining a competitive edge. The company can allocate resources to enhance existing products, explore new treatment options and improve technological capabilities.
Technological Roadmap: The participation of insiders in the offering may indicate confidence in the company's upcoming technological advancements. This capital can support not only the development of new products but also the integration of advanced technologies like AI and machine learning in dermatologic treatments. This can lead to more effective and personalized treatment options, potentially driving future revenue growth.
Long-Term Vision: By securing additional funds, STRATA can focus on long-term projects that require sustained investment. This includes potential clinical trials, regulatory approvals and market expansion efforts. A well-funded technological roadmap allows the company to plan strategically and deliver innovative solutions to the market.
HORSHAM, Pa., July 23, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the issuance and sale of 665,136 shares of its common stock at an average purchase price of
“The insider participation in this financing shows the conviction in STRATA’s strategic plan, ability to execute, and path to profitability. Our team’s resolve in successfully turning around the business and returning to growth mode is strong, and the collected proceeds from this financing will extend our cash runway,” commented STRATA’s President and CEO Dr. Dolev Rafaeli.
About STRATA Skin Sciences
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure (versus an equipment purchase), installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com
FAQ
How much did STRATA Skin Sciences (SSKN) raise in its recent direct offering?
What was the share price for STRATA Skin Sciences' (SSKN) direct offering on July 23, 2024?
How many shares did STRATA Skin Sciences (SSKN) issue in its July 2024 direct offering?
Did insiders participate in STRATA Skin Sciences' (SSKN) direct offering in July 2024?
